Literature DB >> 18765962

Association of physical and social anhedonia with depression in the acute phase of schizophrenia.

Costas T Kollias1, Vassilis P Kontaxakis, Beata J Havaki-Kontaxaki, Sophia Stamouli, Maria Margariti, Eleni Petridou.   

Abstract

BACKGROUND/AIMS: Researchers have shown interest in the association between anhedonia and depression in schizophrenia. The aim of the current study was to investigate the relationship between physical and social anhedonia with depression in a sample of inpatients with schizophrenia in the acute phase of their illness.
METHODS: Sixty-two patients with acute schizophrenia consecutively admitted at the Eginition Hospital, Department of Psychiatry, University of Athens were assessed using the revised Physical Anhedonia Scale, the revised Social Anhedonia Scale and the Calgary Depression Scale for Schizophrenia.
RESULTS: The Calgary Depression Scale for Schizophrenia score correlated with both physical anhedonia and social anhedonia ratings. The revised Social Anhedonia Scale score significantly correlated to self-depreciation, guilty ideas of reference, pathological guilt, early wakening, suicidality and observed depression. The revised Physical Anhedonia Scale score significantly correlated with depressive mood, self-depreciation, pathological guilt and observed depression. Self-depreciation, pathological guilt and observed depression were correlated with both social and physical anhedonia.
CONCLUSION: Depression in schizophrenia and anhedonia may overlap, and it could therefore be difficult to clinically differentiate them, especially in acute schizophrenia patients. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18765962     DOI: 10.1159/000152378

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  10 in total

1.  Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status.

Authors:  Philip D Harvey; Martin Strassnig
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

Review 2.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

3.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

4.  Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia.

Authors:  Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2011-10

5.  Functional domains as correlates of suicidality among psychiatric inpatients.

Authors:  Zimri S Yaseen; Igor I Galynker; Jessica Briggs; Rachel D Freed; Vilma Gabbay
Journal:  J Affect Disord       Date:  2016-05-30       Impact factor: 4.839

6.  Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.

Authors:  Henrik Walter; Hannes Kammerer; Karel Frasch; Manfred Spitzer; Birgit Abler
Journal:  Psychopharmacology (Berl)       Date:  2009-06-12       Impact factor: 4.530

7.  A study of physical anhedonia as a trait marker in schizophrenia.

Authors:  Shobit Garg; Christoday R J Khess; Sumit Khattri; Preeti Mishra; Sai Krishna Tikka
Journal:  Ind Psychiatry J       Date:  2018 Jul-Dec

8.  Vitamin D supplementation improves anxiety but not depression symptoms in patients with vitamin D deficiency.

Authors:  Cuizhen Zhu; Yu Zhang; Ting Wang; Yezhe Lin; Jiakuai Yu; Qingrong Xia; Peng Zhu; Dao-Min Zhu
Journal:  Brain Behav       Date:  2020-09-18       Impact factor: 2.708

9.  Structure of Negative Symptoms in Schizophrenia: An Unresolved Issue.

Authors:  Manuela Russo; Selman Repisti; Biljana Blazhevska Stoilkovska; Stefan Jerotic; Ivan Ristic; Eldina Mesevic Smajic; Fitim Uka; Aliriza Arenliu; Stojan Bajraktarov; Alma Dzubur Kulenovic; Lidija Injac Stevovic; Stefan Priebe; Nikolina Jovanovic
Journal:  Front Psychiatry       Date:  2021-12-14       Impact factor: 4.157

Review 10.  MDMA for the Treatment of Negative Symptoms in Schizophrenia.

Authors:  Mitchell D Arnovitz; Andrew J Spitzberg; Ashkhan J Davani; Nehal P Vadhan; Julie Holland; John M Kane; Timothy I Michaels
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.